CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...
What started out as shoulder pain turned into a living nightmare for a Melbourne girl and her family after doctors discovered a large mass in the eight-year-old’s chest, which turned out to be a rare ...
Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...
A fasting-derived ketone metabolite reshapes CAR T cell metabolism and gene activity, boosting immune cell expansion, energy ...
Detailed price information for Citius Pharmaceuticals Inc (CTXR-Q) from The Globe and Mail including charting and trades.
After weeks of doctor visits and her condition worsening, Emma Operacz was given an unexpected diagnosis ...
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), ...
Topline data of investigator-initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response ...
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius ...
The Kathmandu Post on MSN
Nepal approves first domestically produced CAR T-cell therapy
Kathmandu, March 7 -- Nepal has approved its first domestically manufactured CAR T-cell therapy for clinical use, marking a milestone in the country's cancer treatment capabilities. The Department of ...
Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) (stock code: 7427) announced that its independently developed novel epigenetic immunoactivator GNTbm-38, with global rights for cancer ...
New research from the University of Minnesota School of Dentistry and Masonic Cancer Center is providing important new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results